BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24188213)

  • 1. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.
    Washida K; Ihara M; Nishio K; Fujita Y; Maki T; Yamada M; Takahashi J; Wu X; Kihara T; Ito H; Tomimoto H; Takahashi R
    Stroke; 2010 Aug; 41(8):1798-806. PubMed ID: 20595663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
    Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
    Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
    Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
    Tsukuda K; Mogi M; Iwanami J; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    Hypertension; 2009 Oct; 54(4):782-7. PubMed ID: 19635982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
    Tiyerili V; Becher UM; Aksoy A; Lütjohann D; Wassmann S; Nickenig G; Mueller CF
    Cardiovasc Diabetol; 2013 Feb; 12():30. PubMed ID: 23374104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
    Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
    Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
    Li H; Lu W; Cai WW; Wang PJ; Zhang N; Yu CP; Wang DL; Liu BC; Sun W
    Pulm Pharmacol Ther; 2014 Jun; 28(1):17-24. PubMed ID: 24269521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.